The global oncology pricing, reimbursement and market access report provides analysis and evaluation of the current and prospective economic burden of cancer treatment in the US, Canada, Germany, France, UK, Italy, Spain, Japan, Australia, Brazil, Russia, India, China. This report also outlines historical and current healthcare status for the selected markets with respect to expenditures along with the healthcare system that governs medical access.

In this report, we provide comprehensive view on some of the trends for top-seller oncology drugs including payer’s perspective on cancer outcomes, impact of these high cost drugs, standard guidelines preferred for different cancers, availability and costs of oncology therapeutics and complexity in cancer treatments as well as epidemiology of different cancer types.

How this report will benefit you
In this brand new 292-page report you will receive 98 charts– all unavailable elsewhere.

The 292-page report provides clear detailed insight into the global oncology pricing, reimbursement & market access. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope
Key questions answered by this report:

  • Factors Affecting Pricing and Reimbursement Decision
  • Pricing Negotiations and Discounts
  • Reimbursement Policies
  • Role of HEOR and Economic Value Planning
  • Drug Patent Expiry and Effects on Pricing
  • Cost-Effectiveness Analysis

This report discusses healthcare system, pricing & reimbursement process, HTA, oncology cost of treatment, payer insights, healthcare expenditure, health coverage, key formularies, role of pharmacists, regulatory & approval process for these countries:

  • United States
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Japan
  • Australia
  • Brazil
  • Russia
  • India
  • China

Discussion on parallel import and its impact in the US and Europe.